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Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection continues to be a major 
public health concern, worldwide. HIV infection has increased the TB incidence over the past twenty 
years, making it hard to eliminate TB. At the same time, TB continues to be responsible for 
approximately 30% of deaths among HIV-infected individuals. Emtricitabine (FTC), efavirenz 
(EFV), and tenofovir (TFV) are constituents of a one-day-pill, AtriplaTM, which was approved in 2006 
by the Food and Drug Administration (FDA). AtriplaTM is a triple combination anti-HIV drug that 
provides an efficient dosing plan. Streptomycin (STR), kanamycin (KAN), and ofloxacin (OFL) are 
second-line anti-TB drugs used to treat multidrug-resistant/ extensively drug-resistant tuberculosis 
(MDR/XDR-TB). The worldwide increase in the prevalence of anti-TB drugs resistance is of concern 
to researchers since it remains one of the most significant threats to the community. Co-prescription 
of anti-HIV and anti-TB drugs poses a challenge of drug-drug interactions, which causes adverse 
effects. Therapeutic drug monitoring (TDM) seems to be the tool for a solution to these problems 
since it personalizes doses thus reducing drug toxicity. LC-MS/MS methods with short run times are 
required to produce effective TDM studies. Therefore, this study aimed to evaluate the new Ascentis 
Express column technologies [pentafluorophenylpropyl (F5), octadecyl (C18), biphenyl, and reversed 
phase amide (RP-Amide)] and their applicability to the simultaneous quantification of current first-
line anti-HIV treatment Atripla. It also aimed to develop, optimize and validate a liquid-
chromatography tandem mass spectrometry (LC-MS/MS) methods for the simultaneous 
quantification of anti-HIV drugs (FTC, EFV, and TFV) and second-line anti-TB drugs (STR, KAN, 
and OFL) in rat plasma for the usage of TDM. The currently used HPLC columns have longer run 
times making them impractical in a point of care environment since the number of patients and 
diseases is globally increasing. There are also no or very few studies regarding the LC-MS/MS 
method of simultaneous HIV and TB drugs for HIV positive TB patients. The biphenyl column 
showed consistency and optimum performance with regard to the number of theoretical plates, 
resolution and peak asymmetry factor. It showed good separation and overall effectiveness. However, 
this does not rule out other columns for other purposes intended to be accomplished. The LC-MS/MS 
method developed for the simultaneous quantification of anti-HIV drugs and second-line anti-TB 
drugs was short to eleven minutes and met all the recommendations by the European Medicines 
Agency (EMA) guidelines for bioanalytical method validation. The new HPLC column matrices (F5, 
C18, biphenyl, and RP-Amide) offer various benefits such as the potential of saving solvents and 
short runtimes, essential in TDM studies. Therefore, the usage of the new HPLC column technologies 
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will be beneficial in a point of care environment in terms of saving time and money. The LC-MS/MS 
method validated in this study can be used in clinical trials and in the simultaneous determination of 
the effective plasma concentrations of anti-TB and anti-HIV drugs, making it a strong candidate for 
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1.1 Human immunodeficiency viral infection 
The historical evolution of the Human Immunodeficiency Virus (HIV) and Acquired Immune 
Deficiency Syndrome (AIDS) is very noteworthy. The first human HIV infection is likely to have 
occurred around 1933 in Africa due to cross-species transmission of the disease [1-3]. From Africa, 
it was presented in Haiti around 1969 and thereafter, in New York City (America) around 1972 [1-
3]. When the first case of AIDS was recognized in 1981, HIV had been present in the United States 
for ten years [1-4]. 
In 2016, the approximate number of HIV positive individuals was 36 700 000 and 7 100 000, globally 
and in South Africa, respectively [5]. As of late, highly active antiretroviral therapy (HAART) has 
become an essential treatment strategy for patients suffering from HIV infection [6]. With the 
widespread utilization of antiretroviral drugs, the survival rate of HIV positive patients has 
significantly improved. Antiretroviral drugs ensure the patient’s health is improved by increasing 
CD4 T-cells, fighting opportunistic infections, reducing time spent in hospital and regaining of body 
weight [6]. 
The virus’s main objective, when it invades a human host is to multiply and replicate itself as many 
times as possible [7-9]. Its life cycle has six stages (Figure 1) [9]. The HI virus firstly attaches and 
enters a human cell [9-13]. When it enters the cell, its genetic code is in the form of ribonucleic acid 
(RNA). However, when it enters the host cell, RNA is transformed to deoxyribonucleic acid (DNA), 
so it could incorporate itself into the genetic machinery of the human cell using the enzyme called 
reverse transcriptase (RT) [9-13]. RT enzyme reads and transcribes the viral RNA sequence to 
complementary DNA [14-16]. The newly formed viral DNA then integrates with that of the human 
cell and triggers it to produce nucleotide sequences of the virus which is then referred to as the 
provirus. [9-13]. In addition to producing its nucleotides, it also produces long proteins which are cut 
into shorter proteins by a viral protease enzyme [9-13]. Some of these short proteins are used to form 
more viral enzymes, while the others are transformed to virus structural elements. The mature HIV 
virion then buds off the cell to infect other cells in the body [9-13]. Infected individuals are introduced 
to HIV treatment that will reduce rapid viral replication [9-13].  
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1.2 Antiretroviral therapy (ART) 
The purpose of ART is to decrease and maintain the viral load in plasma at the lowest levels possible 
[17]. This antiretroviral therapy brings about the gradual recovery of the immune system in many 
patients, greatly reducing the risk of disease progression and death. Adherence to antiretroviral 
treatment is critical to guarantee viral control, and reduction [17].  
There are currently five classes of antiretroviral therapy (ART) available in South Africa, namely; 
nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), [18-20] non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), [18-20] protease inhibitors (PIs), [21-23] integrase inhibitors 
(InSTIs) [24-26] and fusion inhibitors [27, 28]. Each of these classes inhibits a specific stage in the 
HIV replication cycle (Table 1, Figure 1).  
Table 1: Mechanism of action for ART classes 
ART class Drug Mechanism of action Reference 





Inhibit transcription of 
viral RNA to DNA by 
mimicking the natural 
building blocks of DNA  
[9, 27, 29] 
NNRTIs Efavirenz (EFV) 
Nevarapine (NVP) 
Etravirine (ETR)  
Change the conformation 
of the catalytic site of RT 
and completely prevent 
its action  
[9, 27, 29] 
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PIs Ritonavir (RTV) 
Lopinavir (LPV) 
Atazanavir (ATV) 
Inhibit the final 
maturation stages of HIV 
replication, resulting in 
the formation of non-
infective viral particles  
[27, 29] 
InSTIs  Raltegravir (RGV) 
dolutegravir (DTG) 
Inhibit the transfer of 
proviral DNA strands into 
the host chromosomal 
DNA  
[27, 29] 
Fusion Inhibitors Maraviroc (MRC) 
enfuvirtide (ENF) 
Bind to viral gp120 or 
gp41 or host cell CD4+ or 
chemokine (CCR5) 
receptors in order to 
prevent fusion of the HIV 







Figure 1: Antiretroviral classes mechanism and site of action (Figure is reused with permission from 
ref [28]). Copyright © 2011 Elsevier Ltd 
South Africa has recently adopted a recommendation by the World Health Organization (WHO), that 
all HIV positive patients should be on ART regardless of their CD4 count [30]. Anti-HIV drugs are 
available as a fixed-dose combination and were implemented for best patients’ benefits. Among the 
fixed-dose combination drugs available for HIV treatment, there are triple fixed-dose combinations, 
which generally consists of two NRTIs and an NNRTI or PI, for example, a one-day-pill, AtriplaTM, 
which was approved in July 2006 by the US Food and Drug Administration (FDA). It comprises of 
two NRTIs (FTC and TFV-DP), and one NNRTI (EFV) (Figure 2, 3 and 4) [31]. Of all fixed-dose 
combination treatments accessible now, Atripla™ presents the most effective dosing plan and the 










Figure 2: FTC drug structure 
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FTC (Figure 2) also known as Emtriva or 5-fluro-1-(2R, 5S)-[2-9hydroxymethyl]-1,3-oxathiolan-5-
yl). It is classified as an NRTI that works against hepatitis B virus and HIV types I and II. FTC 
produces emtricitabine 5′-triphosphate by phosphorylation carried by cellular enzymes, which 
competes with deoxycytidine 5′-triphosphate and stops the new string of nucleotides that form the 
provirus [34]. 
A study by Molina et al., (2004), found the time at maximum plasma concentration (Tmax) for FTC to 
be 1.8 hours with the maximum plasma concentration (Cmax) of 1.8 mg/L and minimum plasma 
concentration (Cmin) was found to be 0.04 mg/L when 200 mg of FTC on prescription was orally 
dosed once-daily for each patient [35]. In another study, Blum et al., (2007), found a Tmax of 3.02 
hours in plasma with a Cmax of 1.77 mg/L and the Cmin was found to be 0.064 mg/L when 200 mg of 
FTC was orally dosed once-daily for each patient [36].  
Another way of determining the effectiveness of a drug is to determine its inhibitory concentration. 
A study by de Lastours et al., (2011), found FTC to have a concentration at which 50% infection was 
inhibited (IC50) of 2 ng/mL against wild-type HIV in peripheral blood mononuclear cell [37] Another 
study, Saravolatz, (2006), found FTC to have an IC50 of 0.01 µmol/L in peripheral blood mononuclear 
cells in vitro activity against HIV [38]. 
Adverse effects of this drug includes the development of a rash, back pain, skin discoloration 
particularly on the soles of the feet and palms, abdominal pain, paresthesia, anxiety, pneumonia, 
urticarial, arthralgia, fever, increased cough, myalgia, dyspepsia, peripheral neuropathy, allergic 






Figure 3: EFV drug structure 
EFV (Figure 3) also known as Sustiva or (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-
(trifluoromethyl)-1H-3,1-benzoxazin-2-one. It belongs to the NNRTI class and is effective against 
HIV type I [40]. A study by Veldkamp et al., (2001), found the Tmax of EFV to be 2 hours in plasma 
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with the Cmax of 3.63 mg/L and Cmin was found to be 1.55 mg/L when 600 mg once daily was orally 
dosed for each patient [41]. Another study by Molina et al., (2004), found the Tmax of 2.5 hours in 
plasma with the Cmax of 2.5 mg/L and Cmin was found to be 1.0 mg/L when 600 mg of EFV once daily 
was orally dosed for each patient [35]. 
A study by Adkins and Noble, (1998), found that EFV demonstrated good inhibitory activity against 
wild-type HIV-1 replicative spread in primary lymphoid and monocytoid cell cultures with 
concentration producing 95% inhibition (IC95) of 1.5 to 3.0 nmol/L [40]. Another study by Parkin et 
al., (2004), found EFV to have an IC50 of 1.6 nmol/L against wild-type HIV-1 in human plasma cell 
culture [42]. 
Adverse effects of this drug include insomnia, inability to concentrate, dizziness, abnormal dreams, 














Figure 4: TFV drug structure 
TFV-DP also known as Viread or 9-[(R)-2-[[bis[[(isopropoxycarbonyl) oxy] methoxy] phosphinyl] 
methoxy] propyl). TFV-DP is an NRTI under the class of acyclic nucleoside phosphonates and is 
effective on different drug-resistant HIV type I strains in vitro. TFV-DP is a prodrug found as 
tenofovir (TFV) (Figure  4) which is chemically described as; 9-[(R)-2-(phosphonomthoxy)-propyl] 
adenine) in blood plasma and converts intracellularly to its active metabolite by diphosphorylation 
[34]. A study by Du et al., (2017), found the Tmax of TFV to be 1.3 ± 0.4 hours in plasma with the 
Cmax of 447.1 ± 217.4 ng/mL when 300 mg once daily was orally dosed for each patient [44]. Another 
study by Blum et al., (2007), found the Tmax of 2.43 hours in plasma with the Cmax of 297 ng/mL when 
300 mg of TFV, once daily was orally dosed for each patient [36].  
A study by de Lastours et al., (2011), found TFV to have an IC50 of 10 ng/mL against wild-type HIV 
in peripheral blood mononuclear cells [37]. Another study by Grayson et al., (2010), reported TFV to 




Adverse effects of this drug include vomiting, renal failure, asthenia, nausea, renal toxicity, headache, 
proteinuria, diarrhea, flatulence, and decreased bone mineral density[43]. 
Most of the adverse impacts of antiretroviral drugs come from drug-drug interactions [46]. The study 
on discontinuation of AtriplaTM as first-line therapy in HIV-1 infected individuals that was conducted 
by Scourfield et al., (2012), found that AtriplaTM is an effectual first-line antiretroviral treatment, yet 
roughly one of every five of all people starting AtriplaTM should change treatment, usually due to side 
effects such as spontaneous abortions, rash, allergic reactions, diarrhoea, nausea, vomiting, mild and 
transient headaches, central nervous system (CNS) toxicity and dizziness [39, 47, 48]. 
Patients are always sceptical and have queries regarding drug toxicity, drug-to-drug interactions and 
drug resistance. A few investigations have shown a connection between efficacy and/or toxicity and 
plasma drug concentrations. Thus, therapeutic drug monitoring (TDM) of antiretroviral drugs is 
critical in clinical maintenance, in selecting the best dosage regimen, personalized to each patient to 
lessen the danger of virological failure from low plasma drug concentration and to prevent the toxicity 
associated with high plasma concentrations [31]. In scientific research, it is broadly acknowledged 
that an adherence level of no less than 90% is important to control the infection adequately in order 
to evade the danger of mutations and to avoid the occurrence of drug-resistant strains and drug failure 
[17]. 
1.3 Tuberculosis (TB) 
South Africa is one of the countries experiencing a higher burden of TB, with the WHO estimating 
the prevalence of about 438,000 of people with active TB in 2016 [5]. Tuberculosis (TB) is caused 
by a bacterium called Mycobacterium tuberculosis (M.tb) which is an acid-fast and alcohol bacillus. 
It belongs to a group of microorganisms called M.tb complex [49]. Tuberculosis is an ancient human 
disease which primarily affects the lungs, resulting in pulmonary diseases. Extrapulmonary TB 
affects different organ systems, particularly, the central nervous system, the respiratory system, the 
skin, the gastrointestinal system, the liver, the musculoskeletal system, the lymph reticular system, 
and the reproductive system. The symptoms of this disease include a bad cough that lasts 3 weeks or 
longer, fever, fatigue, weight loss, coughing up mucus or blood, hemoptysis, loss of appetite, night 
sweats and sputum expectoration [50, 51]. TB is still responsible for a large burden of mortality and 
morbidity globally [49]. In 2016, there were approximately 10.4 million new (incidents) TB cases 
around the world, 90% of which were adults [5]. 
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1.4 HIV-TB co-morbidity 
Tuberculosis is still a major cause of death in developing nations particularly among people with a 
repressed immune system. [52]. HIV alters the clinical form of TB from a gradually advancing disease 
to one with a higher death rate [53, 54]. In 2016, WHO approximated that amongst people with latent 
TB infection (LTBI), individuals who are HIV-positive have a 26-fold-higher danger of the 
development of active TB when compared to those who are HIV-negative [53]. The HI Virus attacks 
the body's immune system by lessening the number of CD4-T cells, which are important in achieving 
a regulated active immune response to pathogens [52, 55]. This then brings about the loss of the 
body's capacity to stop the spread of the M.tb from localized granulomas leading to the spread of 
infection. TB can bring about the depletion of the CD4+ cells and increment of the viral load thus 
speeding up the advancement of HIV disease to AIDS [53, 54].  
TB accounted for 22% of worldwide mortality in people with HIV/AIDS in 2016 [5]. In 2008, South 
Africa accounted for 24% of HIV and TB incidence in the world while having just 1% of the planet’s 
population [53]. This demonstrates that HIV is still the largest risk factor for TB around the world, 
and in locations where HIV incidence is high, the TB-HIV co-morbidity is rapidly growing [53]. In 
2016, WHO estimated that 59% of TB incidence in South Africa is co-infected with HIV and 88% is 









Figure 5: Co-epidemics of TB and HIV over the past ten years in South Africa (Data obtained with 





























Clinical symptoms of TB in HIV positive individuals vary from classic manifestations of weight loss, 
prolonged fever, night sweats, productive cough, or haemoptysis, to negligible or nonspecific 
manifestations [54]. 
HIV patients co-infected with TB require an integrated co-treatment for these two diseases since TB 
is an opportunistic disease and it arises after the first couple of months in HIV positive patients that 
are only on ART [54]. Simultaneous therapy of both HIV and TB, considering the available 
pharmacokinetic evidence from investigations of these two diseases, individually, has appeared to be 
possible and proficient in managing the diseases and provides better survival in different clinical 
backgrounds [54, 56]. 
1.4.1 Tuberculosis drug resistance 
M.tb has natural, unsurprising rates of chromosomally borne mutations that present resistance to 
antimicrobial drugs. These mutations are not related to each other; thus, resistance to a drug is 
commonly on a certain drug group targeting a specific stage in TB life cycle. The rise of drug 
resistance signifies the survival of random previous mutations [57].  
In 2016, an estimated number of 490 000 individuals globally developed multidrug-resistant TB 
(MDR-TB) [5]. South Africa presented 3.4% new cases of individuals who developed MDR-TB in 
2016 [5]. The development and increment of multidrug-resistant strains (MDR-TB; described as 
resistance at least to rifampicin (RMP) and isoniazid (INH) and extensively drug-resistant (XDR-
TB); described as MDR in addition to extra resistance to no less than one fluoroquinolone and one 
second-line injectable drug) of M.tb has been disturbing experts around the world [53, 58]. These 
tuberculosis strains show low cure rates and high death rates because of challenges in their treatment 
[58]. Additionally, HIV seems by all accounts to be an unassuming danger factor for MDR-TB. In 
the latest meta-examination, the likelihood of MDR-TB was 1.26-fold higher amongst those who are 
HIV-positive than amongst those who are HIV-negative [47]. High death rates due to MDR-TB  and 
in a few cases, XDR-TB prevalence, as well as transmission, has been most noticeable in individuals 
with HIV [53]. 
Following the resistance of some M.tb strains to first-line TB drugs, there was the vital need for the 
development of second-line drugs for tuberculosis treatment. Second-line TB drugs comprise of 
fluoroquinolones, aminoglycoside, injectable agents, oral bacteriostatic and anti-TB drugs with less 
evidence on effectiveness and/or long-term safety in the treatment of MRD-TB/XDR-TB [59]. The 
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study of the new treatment against TB assumes an essential part in decreasing the occurrence and 
mortality, important to accomplish worldwide objectives set up by the WHO [58]. 
1.4.2 Treatment of drug-resistant TB 
Discontinuation of the standard TB treatment may lead to drug resistance. Second-line TB drugs, 
which are expensive and have more side effects will then be required to treat MDR-TB. Ofloxacin 
(OFL), [60-62] streptomycin (STR) [63-65] and kanamycin (KAN) [66-68] are among the second-










Figure 6: OFL drug structure 
OFL (Figure 6) is a fluoroquinolone that is used to treat MDR-TB and also works against urethral 
chlamydia infections, Streptococcus pneumoniae pulmonary infections and effectively eradicate 
staphylococcal infections [69, 70]. A study by Yuk  et al., (1991), found the Tmax of OFL to be 1.74 
± 0.57 hours in plasma with the Cmax of 3.14 ± 0.53 µg/mL when 400 mg once daily was orally dosed 
for each volunteer [71]. Another study by Lode et al., (1987), found the Tmax of 1.9 hours in plasma 
with the Cmax of 3.51 ± 0.7 µg/mL when 400 mg of OFL, once daily was orally dosed [72].  
Minimum inhibitory concentration (MIC) is important for determining the effectiveness and 
susceptibility of a drug. A study by Heysell et al., (2015), found 14 OFL-susceptible isolates of M.tb 
with the MICs of ≤ 1μg/mL and nine OFL-resistant isolates with the MICs of ≥ 8 μg/mL on the 96-
well Sensititre MYCOTB plate [73]. Another study by Chen et al., (1989), found OFL-susceptible 
strains of M.tb with the MIC of 2 μg/mL when determined in 7H12 broth radiometrically [74].  
Adverse effects include nausea, anorexia, vomiting, diarrhoea, skin or hypersensitivity reactions, and 






















Figure 7: STR drug structure 
STR (Figure 7) is an aminoglycoside bactericidal originated from Streptomyces griseus that is 
utilized as part of the treatment of TB and sensitive Gram-negative diseases. Individuals with MDR-
TB are given ethambutol, STR, and moxifloxacin for a year and a half [57].  A study, Park et al., 
(2015), found the Tmax of STR to be 1.0 (0.5–1.5) hours in plasma with the Cmax of 42.0 ± 10.8 mg/L 
when 1 g once daily was dosed for each volunteer [75]. In a study, Zhu et al., (2001), where 18 mg/kg 
of STR was intramuscularly (IM) dosed, Tmax  in plasma was found to be 1.51 (0.58–2.70) hours with 
the Cmax of 42.6 (2.90–85.2) mg/L [76]. In nother study, Prasad et al., (1978), where 20 mg/kg of STR 
was IM dosed, Tmax was found to be 0.5 hours in plasma with the Cmax of 12.3 ± 1.79 mg/L [77].  
Susceptibility of M.tb to a drug is determined by MICs. A study, Franzblau et al., (1998), found 18 
strains of M.tb susceptible to STR with the MICs of 2 μg/mL in the BACTEC system and was ≤ 1 
μg/mL by the microplate-based Alamar Blue assay (MABA). For 11 of the 13 strains resistant to 
STR, MIC was 6 μg/mL in the BACTEC system and 2 to 8 μg/mL by MABA. For two resistant 
strains to STR at 6 μg/ml in the BACTEC system, the MICs by MABA was ≥32 μg/ml [78]. Another 
study, Schönfeld et al., (2012), found five (19.2%) strains of M.tb which showed sensitivity to STR 
with MICs below or equal to 4.0 μg/mL and most resistant strains to STR showed MICs above 20 
μg/ml (88.9 %) on Löwenstein–Jensen medium (LJ medium) [79]. 
Side effects incorporate deafness (no wax on otoscopy), rash, deafness, sterile abscesses can develop 
at injection spots and injections are aching, hypersensitivity responses are normal and can be serious, 
dosage ought to be decreased if vertigo, headache, tinnitus, and vomiting take place. Aplastic 
anaemia, agranulocytosis, thrombocytopenia, haemolytic anaemia, lipoid responses, and 

















Figure 8: KAN drug structure 
KAN (Figure 8) is also an aminoglycoside anti-microbial drug that inhibits protein synthesis by 
binding to the ribosomes of the bacteria [80]. A study, Clarke et.al., (1974), found the Tmax of two 
hours in plasma with the Cmax of 18 mg/L after a 7.5 mg/kg IM single dose of KAN [81]. Another 
study, Doluisio et.al., (1973), found similar results, Tmax was one hour in plasma with the Cmax of 23 
mg/L after a 7.5 mg/kg IM dose of KAN in 12 hours [82].  
A study, Bastian et al., (2001), found 36 of 37 kanamycin-susceptible isolates of M.tb with the MICs 
of ≤ 2.5 μg/mL  while all 35 kanamycin-resistant isolates with the MICs of ≥ 5.0 μg/mL by the MABA 
method using 7H9-S broth [83]. Another study, Heysell et al., (2015), found 55 KAN-susceptible 
isolates of M.tb with the MICs of ≤ 2.5 μg/mL and 1 KAN-resistant isolate with the MIC of ≥ 20.0 
μg/mL on the 96-well Sensititre MYCOTB plate [73]. 
Adverse effects of this drug incorporate azotaemia, hearing loss, ataxia, nystagmus, proteinuria, 
eosinophilia, thrush, serum electrolyte abnormalities, stomach pains, tremulousness headache and 
anxiety [56, 57, 84]. 
1.5 Therapeutic drug monitoring (TDM) 
Therapeutic drug monitoring (TDM) is the measurement of specific drug concentrations at timed 
intervals in the patients’ plasma [85]. The main aims of TDM are to avoid therapeutic failures due to 
bad compliance or too low dose of a given drug, as well as adverse or toxic effects due to an excessive 
dose by individualizing therapeutic regimens for ideal patient’s advantage [85, 86]. The utilization of 
TDM in the case of different diseases enables the clinicians to make informed decisions with respect 
to the dosage and the duration of medication treatment [87]. A small number of patients do not adhere 
well to treatment or are in danger of drug-drug interactions or have MDR or XDR TB or have 
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simultaneous disease conditions that further complicate the clinical setting. TDM is especially 
beneficial to these kinds of patients that have a complicated clinical background [87]. 
Drug-drug interactions are likely to occur for HIV positive TB patients using at least three drugs for 
their treatments, combined.  The approved drug guidelines only show drug-drug interactions of two 
drugs, which become inefficient when the patient is treated with  three or more drugs [87]. Under 
these difficult conditions, TDM frequently is the most accessible technique for quantifying these 
interactions and assigning the patient the correct dosage that they need [87]. Comparisons of 
concentration/dose ratios in exposed and unexposed patients are performed using TDM data to study 
drug interactions [88]. 
The plasma drug concentrations are helpful especially for few compounds that have a narrow interval 
between the therapeutic dose and the toxic dose. Tests for a substantially more broader scope of 
compounds, and metabolites might be needed to survey adherence (concordance, consistency) to 
treatment, side effects, acute poisoning, or drug-drug interactions [89].  
1.6 Mass spectrometry 
Mass spectrometry (MS) is amongst the most accurate, reliable, and easily accessible methods to 
identify the atomic and molecular masses of compounds with high precision in a single evaluation 
[90-92]. MS converts analyte molecules into ions; thereafter the analyte’s mass (quantitative) and 
structure (qualitative) can be determined upon detection [93].  
A key component of MS depends on the capacity of electric and magnetic fields to impact the 
movement of charged particles and atoms, ordinarily in a vacuum relative to their mass  and charge 
[90].  Positive or negative charges are obtained upon ionization of an analyte molecule when it is 
introduced into the ionization source of the MS. The ions are separated by the detector on the basis 
of their mass/charge (m/z) ratio after they have travelled through the mass analyzer. A computer 
system records readable signals upon the arrival of the ions at the detector. The signals in a computer 
system are displayed as spectra based on their m/z ratio. Information that can be obtained from mass 
spectral data includes purity of the sample, structure and molecular weight [93].  
Numerous technologies exist for ionization and mass analysis, leading to many various kinds of MS’s 
with various combinations of these two processes. Available ion sources include electrospray 
ionization source (ESI), atmospheric pressure chemical ionization source (APCI), and atmospheric 
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pressure photo-ionization (APPI). Mass analyzers available include ion trap, hybrid, time of flight, 
and quadrupole analyzers [91]. 
ESI utilizes electrical energy to help with the transmission of ions from a liquid phase to a gas phase 
before they are subjected to mass spectrometric analysis. Ionic species in the liquid phase would, 
therefore, be able to be analyzed by ESI-MS with higher sensitivity. The transmission of ions from a 
liquid into the gas phase by ESI includes three steps: dispersion of a fine spray of charged droplets, 
solvent evaporation and ion ejection from the highly charged droplets tube [93].  
A fine spray of charged droplets is formed at the tip of the capillary after the in-solution samples are 
pumped at 3 to 5 kV and nebulized. The capillary is normally orthogonal to or off-axis from, the 
passage to the mass spectrometer with a specific goal to reduce contamination. Use of dry nitrogen 
and heat quickly evaporate the droplets, and the residual electrical charge on the droplets is transferred 
to the analytes. Focusing voltages and small apertures are used to transfer the ionized analytes into 
the high vacuum of the mass spectrometer. Detection of negative or positive ions is accomplished 
after the ions have gone through the ion source and mass analyzer [91].  
 
Figure 9: Basic diagram of instrumentation of typical liquid chromatography-mass spectrometry 
(Information obtained from literature [94])  
Under typical circumstances, ESI is viewed as a “soft” ionization source, implying that generally little 
energy is sent to the analyte, and thus little fragmentation takes place. This is as opposed to other MS 
ion sources, for instance, the electron impact source ordinarily utilized in gas chromatography mass 
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spectrometry (GC-MS), which causes extensive fragmentation. It is possible to increase ESI “in-
source” fragmentation by increasing voltages inside the source to increase collisions with nitrogen 
molecules. This has been utilized as part of LC-MS analyses to distinguish compounds with common 
structural characteristics [91]. 
In APCI, nebulization occurs at the tip after the liquid is injected through a capillary. Next to the 
capillary tip, a corona discharge occurs, where gas and solvent molecules are ionized. An analyte is 
then ionized by charge transfer after it has reacted with the ions formed from gas and solvent 
molecules. APCI is especially used for thermally stable and small molecules. In APCI, singly-charged 
ions are dominant, unlike in ESI where multiple charging is dominant. APCI has also been used for 
fat-soluble vitamins and lipids [91, 95-99]. 
In APPI, after nebulization, photons are used to excite and ionize molecules. Simultaneous ionization 
of solvents and ion source gases are minimized by the energy of the photons. In APPI, singly-charged 
ions are also dominant. APPI is used for neutral compounds, for example, steroids [91, 100, 101]. 
The components of a liquid chromatography-mass spectrometry (LC-MS) system (Figure 9) 
incorporate the high-performance liquid chromatography (HPLC) system, the mass spectrometer, the 
autosampler and the ionization source (which connects the MS and the LC). Preferably, these 
components are all controlled by one PC system. The HPLC system is made up of various components 
such as the mobile phase reservoir, pump, injector, and column [102]. It ought to be pointed out that 
to link HPLC with MS; there are a few limitations on the mobile phases and rate of flow that can be 
utilized. Acetonitrile or methanol and water are utilized as mobile phases in reversed phase HPLC 
systems linked with MS. There are many mobile phase modifiers, and these should be volatile in 
many instances. Mobile phase modifiers are additional chemicals to the mobile phase that are 
fundamentally utilized to enhance the chromatography of the analytes of concern. Common mobile 
phase modifiers would incorporate acetic acid, formic acid, and ammonium acetate [103].  
1.6.1 Tandem mass spectrometry 
Two ions with the equal mass-to-charge (m/z) ratio cannot be differentiated by the mass analyzer, as 
would be the case with stereoisomers. In any case, these particles can regularly be differentiated by 
breaking the ions separated and examining the ion fragments using a second mass analyzer. To 
achieve this, mass spectrometers can be designed to store, channel and fragment ions [90]. Since each 
of these tasks may require extra equipment, contemporary multiplexed mass spectrometer systems 
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are frequently hybrids and incorporate more than one mass analyzer, equipped for multistage 
operation. This multiplex method is mostly denoted as coupled mass spectrometry, or MS/MS, to 
depict the two phases of analysis [90]. 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) quantification has become the 
gold standard tool due to its capabilities of ion fragmentation, which is essential for identification 
of analytes in matrices [90, 104-113]. To distinguish analytes of the same mass, ion fragmentation 
for each analyte is required [90]. Coupled MS enhances identification by means of fragmentation in 
light of the fact that the coupled mass spectrum may give a different profile of the fragment ions, 
representing a chemical structure. Ordinarily, MS/MS analysis is achieved by a collision of a chosen 
ion with inert gas molecules, for example, argon or nitrogen, and the subsequent fragments go through 
mass analysis. MS/MS is utilized to analyze lipids, peptides, small oligonucleotides and structurally 
characterize carbohydrates [94]. 
Quadrupole time-of-flight (QqTOF) (Figure 10) is one of the coupled mass spectrometers and is 
depicted in the most straightforward manner as a triple quadrupole with the last quadrupole area 
substituted by a TOF analyzer [114]. Triple quadrupole instruments have capabilities to distinguish 
the chemical backgrounds which result in higher sensitivity and selectivity [92]. Most quadrupole 
analyzers function at <4000 m/z and scan speeds up to 1000 m/z per second or more [91]. 
The precursor ion which is the targeted analyte is selected by the first quadrupole (Q1) based on the 
mass. It is then permitted to collide with argon or nitrogen collision gases in a second r.f. only 
quadrupole collision cell (Q2) where the collision activates the precursor ion to go through 
fragmentation. This process is called collision-induced dissociation (CID). The TOF as a third 
quadrupole mass analyzer (Q3) monitors the product ions that result from CID and gives structural 
facts [93].  
The quadrupole is capable of monitoring different specific m/z values by stepping the voltages. This 
is essential in enhancing the detection limits of precursor ion since detector time for detecting specific 
ions is increased rather than wasting it doing the full scan of the analyte. Stepping the voltages is 
much faster [91]. When Q1 is to monitor one specific m/z ratio, it filters out other molecular ions 
having different m/z ratios. This is a purification step inside the MS system, removing time-
consuming and complex sample purification steps before the MS analysis [93]. 
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Multiple-reaction monitoring (MRM) is a mode of data acquisition usually utilized in ESI-MS/MS 
quantification analysis. Both Q1 and Q3 are static for a pre-determined pair of precursor and product 
ions [93]. In ion trap analyzer, ions are trapped in a 3-dimensional space by three hyperbolic 
electrodes using radio frequency and static voltages. A mass spectrum with regards to m/z ratio is 
created after the ejection of ions from the trap. An exciting voltage can be applied instead, while other 
ions are ejected, to isolate a specific ion in the trap. To induce fragmentation, an inert gas can be 
established. In ion trap analyzer, MSn capabilities are produced since ion trap is able to fragment and 
isolate ions numerous times in series prior the attainment of the final mass spectrum [91, 115, 116]. 
 
Figure 10: Schematic diagram of Quadrupole time-of-flight (QqTOF) tandem mass spectrometer 
(Figure is reused with permission from  ref [114]). Copyright © 2001 John Wiley & Sons, Ltd 
The sample is ejected through the electrospray and the targeted analyte is selected by the first 
quadrupole (Q1) based on the mass and then it collides with a gas (argon or nitrogen) in a second r.f. 
on quadrupole collision cell (Q2) where the collision activates the analyte for fragmentation. The 
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TOF as a third quadrupole mass analyzer monitors the product ions that result from CID and gives 
structural information [93].  
1.7 New HPLC column matrices 
The new HPLC column matrices that offer various benefits are essential in TDM studies of various 
diseases. Currently, available HPLC methods use old column technology that require longer runtimes 
and is not feasible in a point of care environment. The new HPLC column matrices have the potential 
of short runtimes and saving solvents.  These new HPLC column matrices are commercially available 
from different manufacturers. These new HPLC column matrices include the  
pentafluorophenylpropyl (F5), octadecyl (C18), biphenyl, and reversed phase amide (RP-Amide) 
[117]. 
1.7.1 The pentafluorophenylpropyl matrix 
The pentafluorophenylpropyl (F5) (Figure 11) bonded phase has firm dipole potential (polar 
interaction) from the carbon-fluorine bonds, capacity to interact through charge-exchange interactions 
and the pi-pi interaction potential due to the electronegativity of the fluorine atoms. It is said to give 
advanced shape selectivity of analytes differing in spatial size and properties due to its firmness nature 
[117]. 
The utilization of fluorinated stationary phases in liquid chromatography has turned out to be critical 
as of late. Fluorinated stationary phases give diverse retention systems; therefore they are time to time 
utilized for the separations not effortlessly acquired utilizing basic C18 phases [117].  
Fluorinated phases have been appeared to show more noteworthy ion-exchange character than their 
alkyl associates [117]. Fluorinated phases frequently give exceptional chromatographic outcomes 
when analytes to be isolated vary in their ionization constants, or where some ion-exchange is vital 
for the retention of polar metabolites or degradation compounds [117]. Another imperative 
characteristic of the fluorinated phases lies in their noticeable increased shape selectivity compared 
to the regular stationary phase packings. Fluorinated phases, thus, are regularly better than their alkyl 










Figure 11: Chemical structure of pentafluorophenylpropyl stationary phase 
1.7.2 The octadecyl matrix 
The new octadecyl (C18) column has been described to function better than the normal C18 columns 
and it also gives amazing liquid chromatography speed [117]. When developing a new method, it is 
advisable to start off with this column. It has a Fuse Core molecule which gives a compact silica core 
encompassed by a fragile porous shell of high-purity silica [117].  
Its porous shell, minute particle size, and simplistic diffusion path enable this column to display its 
very high column efficiency at low pressure system [117]. The new C18 column proves to be the best 
option within a laboratory and research environments because of its abilities of low operational 
pressure, increased efficiency, reduced solvent usage and runtime. The stable, reverse-phased 
octadecyl (Figure 12) Fused-Core particle platform is functional for compounds that are basic, acidic 






Figure 12: Chemical structure of octadecyl stationary phase 
1.7.3 The biphenyl matrix 
The biphenyl (Figure 13) phase provides alternative selectivity to drug metabolites and 
pharmaceutical analytes that are hard to resolve or that are not very much retained on phenyl and 
conventional alkyl (C18) bonded phases [117]. HPLC columns using Fused-Core particle innovation 
can give both the high and fast proficiencies of small particles while keeping down backpressures. 








Figure 13: Chemical structure of biphenyl stationary phase 
1.7.4 The reversed phase amide  
The reversed phase amide (RP-Amide) (Figure 14) column is comprised of the combination of an 
embedded polar group (EPG) stationary phase with the Fused-Core particle [117]. The advantages of 
this column incorporate enhanced peak shape for bases, 100% aqueous compatible reversed-phase 
column and alternative reversed-shape selectivity to C18. The RP-Amide is a combination of modern 
phase technology and innovation particle technology [117]. The Fused-Core particle gives benefits 



























Figure 14: Chemical structure of amide stationary phase 
The RP-Amide gives increased selectivity to polar analytes, particularly those that donate hydrogen 
bond. Amines, phenols, carboxylic acids, and to a lesser degree alcohols, indicate upgraded retention 
on the RP-Amide phase when contrasted with neutral, non-polar compounds [117]. 
The selectivity dissimilarities between the RP-Amide and the C18 can be a helpful feature in method 
development. Most of the times, when peaks co-elute on a C18 phase, it can be replaced with the RP-
Amide. RP-Amide gives stable and reproducible analyte retention in 100% aqueous mobile phases. 
Numerous C18 phases are famous to experience the ill effects of phase collapse under profoundly 
aqueous phase conditions creating a loss of retention [117]. 
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1.8 Bioanalytical method validation 
The primary objective of bioanalytical method validation is to show the reliability of a specific 
method for the determination of an analyte concentration in a biological matrix, for example, urine, 
blood, saliva, serum or plasma. The outcomes of pharmacokinetic studies are utilized to settle on 
important decisions for the efficacy and safety of a therapeutic drug. It is then imperative that the 
bioanalytical methods utilized are validated [118, 119].  
1.8.1 European Medicines Agency (EMA) guidelines 
European Medicines Agency (EMA) guidelines give recommendations for the bioanalytical methods 
validation regarding measuring drug concentrations in biological matrices acquired in 
pharmacokinetic studies and clinical trials [118-120].  
1.8.2 Validation parameters 
1.8.2.1 Lower limit of quantification (LLOQ) 
The lower limit of quantification (LLOQ) is the lowest concentration of analyte in a sample which 
can be reliably quantified [118-120].  
1.8.2.2 Linearity 
The response of the instrument regarding the concentration of analyte should be known and be 
assessed over a specific concentration range. There ought to be one calibration curve for each analyte 
examined in the method validation [118-120]. These will be discussed next. 
1.8.2.3 Accuracy and precision 
The accuracy of a bioanalytical method depicts the closeness of the determined value acquired by the 
method to the analyte’s theoretical concentration. Accuracy is expressed in percentage. The precision 
of the bioanalytical method depicts the closeness of repeated single measures of analyte. Precision is 
expressed as the coefficient of variation (CV) [118-120].  
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1.8.2.4 Matrix effect 
The interference of unintended analytes or other substances in response due to their presence in the 
sample should be evaluated in method validation [118-120].  
1.8.2.5 Stability 
Stability evaluation is completed to ensure that each step that is taken during sample preparation and 
sample analysis, as well as storage conditions utilized, do not affect the analyte’s concentration [118-
120]. 
1.9 Aims and Objectives 
Aims: 
This study aims to evaluate and compare the new column technologies (RP-Amide, F5, C18, and 
biphenyl) and their applicability to the simultaneous quantification of current first-line anti-HIV 
(efavirenz, emtricitabine and tenofovir disoproxil) and/or second-line TB (kanamycin, ofloxacin and 
streptomycin) treatment for the usage of TDM. 
Objectives: 
• To develop, optimize and validate an LC-MS/MS method for Atripla and/or second-line TB 
drugs by determining the lower limit of quantification, linearity, accuracy and precision in 
rat plasma. 
• To determine resolution of the peaks in all the column technologies. 
• To determine the number of theoretical plates for the four column technologies. 






1.10 Outline of the thesis 
Chapter 1 gives background information on the topics covered in the thesis, aims and objectives. 
Chapter 2 presents the submitted paper for publication “Performance comparison of fused core 
particle columns for the quantitation of ARVs in Atripla”. 
In this paper, various columns were compared to determine their efficiency based on the resolution, 
number of theoretical plates and asymmetry factor while developing a quantitative bioanalytical 
method according to EMA guidelines. 
Chapter 3 presents the submitted paper for publication “LC-MS/MS method development and 
validation for simultaneous quantification of first-line HIV drugs and second-line TB drugs in rat 
plasma”. 
In this paper, an LC-MS-MS method for the simultaneous quantification of anti-HIV drugs (FTC, 
EFV, and TFV) and second-line anti-TB drugs (STR, KAN, and OFL) according to EMA guidelines 
was developed, optimized and validated. In the study rat plasma was used as the biological matrix. 
The method developed will be useful for TDM studied. 
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Human immunodeficiency virus (HIV), remains a global concern despite the advent of anti-retroviral 
(ARV) therapy. Many developing countries have now adopted the legislature that states that all HIV 
patients should receive ARV treatment, regardless of CD4+ count. This places significant pressure on 
ARV stores with many developing countries running out of drugs, in addition to these patients may 
encounter adverse treatment outcomes. A possible solution to assist with problem is therapeutic drug 
monitoring (TDM) which will allow for personalized medicine and optimum dosing for each patient, 
thereby reducing the pressure on ARV stores and reducing potential side effects. TDM makes use of 
an analytical technique (commonly LC-MS) to measure drug plasma concentrations, however current 
methods are lengthy and cannot be applied in a point-of-care setting. Recent technological advances 
have led to the development of new HPLC columns with the potential to decrease run times and offer 
enhanced selectivity. Therefore, the aim of this study was to evaluate new chromatographic column 
technologies and their applicability to the simultaneous quantification of the current first-line ARV 
treatment. We evaluated the C18, biphenyl, pentaflourophenyl (F5) and the amide fused core 
columns; based on resolution, peak asymmetry factor, theoretical plates, limit of detection, linearity, 
accuracy and precision of the analytical method. Our results showed that each column offered its own 
advantages and disadvantages for the separation of the current ARV treatment, with the biphenyl 
column performing most consistently.  





Current first line combination antiretroviral therapy (ART) comprises of one non-nucleoside reverse 
transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NTRI’s) [1]. The 
available treatment is a one a day pill known as Atripla, approved by the Food and Drug 
Administration (FDA) in July 2006 [2, 3]. This drug combination comprises of emtricitabine (FTC), 
tenofovir disoproxil (TFV-DP), which belong to NTRI’s, and efavirenz (EFV) an NNRTI’s [4]. It is 
considered to be the most affordable, yet effective regimen and is also available in generic forms [1]. 
In 2012, the World Health Organization (WHO) recommended a law compelling all HIV infected 
individuals to be administered ARV’s as soon as they become aware of being HIV positive, regardless 
of their CD4+ count [5]. ARV therapy can be very expensive for developing countries, which have 
the highest prevalence of the disease with their stores under constant pressure due to the large patient 
demand [6, 7]. Therefore, therapeutic drug monitoring (TDM) should be recommended for optimum 
dosing of infected individuals, thereby reducing pressure on ARV stores and reducing the occurrence 
of adverse drug effects [8]. 
TDM refers to the constant measurement of drug levels in blood and is used to determine the most 
optimal drug dosage required, with minimal toxicity [8], while also being a useful tool to monitor 
patient adherence [9, 10]. TDM takes into consideration factors which can also influence the drug 
therapy regimen, such as methods used in the laboratory for drug testing, weight and age of an 
individual, if individuals suffer from other co-morbidities and drug dosage [9]. It also considers drug 
delivery, absorption, metabolism and elimination rates, and if an infected individual is receiving any 
other form of medication [9]. Analysis of pharmaceuticals and other related compounds have now 
become more efficient due to the developments in high performance liquid chromatography (HPLC) 
and mass spectrometry (MS) analysis of biological samples [11]. Liquid chromatography tandem 
mass spectrometry (LC-MS/MS) quantification has become the gold standard tool for assessing the 
concentration profiles of a wide range of therapeutics in various biological matrices [12-21]. 
LC-MS/MS has universal applicability making it the forerunning technique in analyzing chemical 
and biological mixtures with great precision [11]. There are a number of established and newer 
column technologies available which offer greater selectivity thereby increasing the range of 
compounds that can be quantified [22]. In analytical chemistry, column efficiency can be evaluated 
by parameters such as selectivity, resolution, peak asymmetry and theoretical plates [11]. Efficiency 
refers to the mechanical power of separation of a column and is determined by the particle size and 
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length of a column [23-25]. Selectivity can be defined as the degree to which chemical dissociation 
occurs to determine the analytes present in a mixture [23]. Therefore, in comparing column 
technologies, the length of a column as well as the particle size should be kept as nominal as possible 
in order to decrease run times [23]. The internal diameter, volume, and column bed length are also 
determinants of the quantity of packing material that is contained within the column which also affects 
the flow rate as well as the time taken to complete the analyses [23]. 
Currently, the methods available for the quantification of ARV’s in plasma and brain are relatively 
lengthy [26, 27] for routine point of care analysis. There are a number of new HPLC column 
technologies which offer advanced packing materials, each of them providing remarkable 
performance, efficiency and shortened run times [22].  
Therefore, the aim of this study was to evaluate these new column technologies and their applicability 
to the simultaneous quantification of current first-line anti-HIV treatment. This was be done by 
comparing various determinants of column efficiency while developing a quantitative bioanalytical 
method according to European Medicines Agency (EMA) Guidelines [28]. 
 
2.3 Materials and methods 
2.3.1 Reagents and standards 
EFV was purchased from Adcock Ingram (South Africa), TFV-DP was purchased from Cipla Life 
Sciences (South Africa) and FTC was purchased from Mylan (South Africa). Internal standards, 4-
(4-carboxybenzyl)-2H-1, 4-benzoxazin-3(4H)-one (CBB), adefovir dipivoxil (ADV-DP) and 
zidovudine (ZDV) were purchased from Sigma Aldrich, DLD Scientific (South Africa) and Aspen 
Pharmacare (South Africa), respectively. LC-MS grade solvents; acetonitrile (ACN) and methanol 
(MeOH) were purchased from Sigma Aldrich. Analytical grade formic acid (FA) was purchased from 
Merck Millipore (Merck, South Africa). Water was purified with a Milli-Q purification system from 
Millipore Corporation (Bedford, MA, USA). HLB-SPE cartridges (30 mg, 1.0 mL) were purchased 
from Supelco-Sigma (St. Louis, MO, USA).  
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2.3.2 Instrumentation  
The liquid chromatography tandem mass spectrometry (LC-MS/MS) system consisted of an Agilent 
Technologies 1100 (Agilent, Germany) coupled to a MicroTOF-Q II electrospray ionization (ESI) 
time-of-flight-mass spectrometry (TOF-MS) instrument (Bruker Daltonics, Bremen, Germany). The 
raw data were analysed with Data Analysis 4.0 SP 5 (Bruker Daltonics).  
2.3.3 Mass spectrometric analysis  
The MS conditions were optimized for the detection of EFV, FTC, TFV-DP and their internal 
standards CBB, ZDV and ADV-DP, respectively. Acquisition parameters were: source type, ESI; ion 
polarity, positive; end plate source, -500 V; nebulizer, 1.8 bar; dry gas, 8.0 L/min; capillary, -5500V; 
dry temperature, 200 ◦C; mass range, m/z 100 → 600; collision cell radiofrequency, 200 Vpp; 
collision energy, 14 eV.  
2.3.4 Preparation of calibration curve and quality control standards 
Separate stock solutions of target analytes and internal standards were prepared by dissolving 1 mg 
of each drug in 1 mL of MeOH then stored at -20 ◦C. Appropriate serial dilutions of the stock solutions 
were formulated according to the working standard solutions. Calibration standards were concocted 
by appropriate dilutions to give final concentrations of 10, 20, 60, 100, 250, 500, 1000, 1500, and 
2000 ng/mL for FTC and EFV; and 2, 10, 20, 60, 100, 250, 500, 750 and 1000 ng/mL for TFV-DP. 
The quality control (QC) standards at lower limit of quantification (LLOQ), low-quality control 
(LQC), middle-quality control (MQC) and high-quality control (HQC) were prepared by appropriate 
dilutions to give final concentrations of 10, 60, 250 and 750 ng/mL for TFV-DP and 20, 100, 500 and 
1500 ng/mL for EFV and FTC. Levels of internal standards were 100 ng/mL for ADV-DP; and 250 
ng/mL for both CBB and ZDV.  
2.3.5 Chromatographic Conditions 
The effectiveness of the four different reversed phase (RP) Ascentis Express columns (Supelco, 
Sigma Aldrich, Germany); C18, biphenyl, pentafluorophenylpropyl (F5) and amide fused core were 
investigated based on their resolution, number of theoretical plates and asymmetry factor. Mobile 
phase A was ultra-pure water (0.1% v/v FA) for both methods and mobile phase B was either MeOH 
(0.1% v/v FA) or ACN (0.1% v/v FA). Separation was possible within 14 min using both gradient 
methods at a flow rate of 0.35 ml/min and a column equilibration time of 4 min. The MeOH gradient 
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was started at 40% mobile phase B and increased to 99% over 12 min, held for 1 min before being 
returned to starting conditions in 1 min. The most optimum ACN gradient started at 10% mobile 
phase B, increased to 99 % over 12 min, held for 1 min and returned to 10% over 1 min. 
2.3.6 Method validation 
2.3.6.1 Accuracy and precision 
Accuracy was determined as the ratio between the calculated concentration of the target compounds 
and their nominal concentrations. Intra-day and inter-day precisions were assessed by an assay of 
three replicates at low, medium, and high QC levels on the same day and on three consecutive days. 
According to the European Medicines Agency (EMA) on bioanalytical method validation, the 
acceptance criterion is ± 15% of theoretical concentration for both accuracy and precision (% RSD) 
except for the LLOQ. The QC levels were as follows; 10, 60, 250 and 750 ng/ml for TFV-DP and 20, 
100, 500 and 1500 ng/ml for EFV and FTC. Internal standard concentrations were 100 ng/mL for 
ADV-DP and 250 ng/mL for CBB and ZDV.  
2.3.6.2 Extraction recovery 
Extraction recovery of the target compounds were estimated at the three QC levels (low, medium and 
high) in three replicates. In brief, 100 µL of rat plasma was spiked with the appropriate amount of 
internal standards, in order to attain the desired QC concentrations. Thereafter, the sample was made 
up to 1mL using LC-MS grade MeOH and vortexed for 1 minute. The mixture was then centrifuged 
at 15 000 rpm, 4 C for 15 minutes. The samples were subjected to SPE using the Supel- SELECT 
HLB: 30mg/1 mL SPE cartridge (Supelco, Sigma Aldrich, Germany), which gave the most 
reproducible recoveries. The SPE cartridge was conditioned with 1 mL of MeOH. The sample was 
then passed (1 mL min-) through the SPE cartridge and the eluent collected in an HPLC vial, prior to 
injection into the LC-MS system.  
2.4 Results and Discussion 
We evaluated four columns with different matrix active groups i.e. C18, biphenyl, F5 and amide. The 
F5 column technology makes use of the pentafluorophenyl functionality which utilizes fluorinated 
stationary phases. Early applications in the effective resolution of paclitaxel have helped such phases 
gain much popularity [29]. Due to the diverse retention systems of fluorinated stationary phases, it is 
frequently utilized for separations that are unachievable on the traditional C18 phase [22]. The amide 
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column stationary phase consists of an embedded polar group (EPG) and has also gained popularity 
as an alternative to the conventional C8 and C18 columns [22]. The advantages of this column include 
enhanced peak shapes for bases and 100 % aqueous compatible. The biphenyl columns are normally 
used when conventional phenyl and alkyl bonded phases are unsuccessful in retaining drug 
metabolites and other pharmaceutical agents [22]. In order to effectively evaluate these new column 
technologies, they were compared to the C18 equivalent which is the preferred choice of column 
when developing a new method [11]. All columns were fused-core particle technology, which 
provides a compact silica core surrounded by a delicate permeable shell of high-purity silica [22].  
The gradient compositions were evaluated for optimum chromatographic retention of the analytes. 
Gradients of MeOH and ACN with water were evaluated for separation efficiencies on each column 
(Figures 1-4). The mass spectrometric conditions were optimized such that the maximum stable 
response was achieved from the precursor ion and the major product ions of each analyte. The 
resultant mass transitions of the analytes were optimised for the protonated molecule and obtained 
via positive electrospray ionization scanning at m/z 248.04 to 130.04, m/z 268.04 to 127.04, m/z 520 
to 288.08, m/z 502 to 256.05, m/z 284.1 to 135.04 and m/z 316.3 to 168.08 for FTC, ZDV (IS), TFV-
DP, ADV-DP (IS), CBB (IS) and EFV, respectively. 
The chromatogram of analytes and internal standards in Figure 1 were obtained using the C18 
column. It was found that the MeOH gradient method resulted in good peak shapes even though 
ADV-DP and CBB couldn’t be separated. The extracted ion chromatogram (EIC) was advantageous 
in differentiating between unresolved peaks on the total ion chromatogram (TIC).  
             
Figure 1: A MeOH gradient and B ACN gradient chromatogram showing FTC, TFV-DP, EFV and 
their respective internal standards using the C18 column (n = 6). The respective LOD’s for FTC, EFV 




The chromatogram of analytes and internal standards in the ACN gradient method resulted in 
separation of FTC from ZDV but the former analyte gave peak splitting while the latter resulted in 
peak broadening and lower intensities. 
The chromatogram of analytes and internal standards in Figure 2 were obtained using the biphenyl 
column, which resulted in excellent separation of FTC, ZDV, TFV-DP, ADV-DP, CBB and EFV 
under both gradient systems. The ACN as the organic mobile phase however gave peak splitting for 
the FTC. 
         
Figure 2: A MeOH gradient and B ACN gradient chromatogram of FTC, TFV-DP, EFV and their 
internal standards using a biphenyl stationary phase (n = 6). The respective LOD’s for FTC, EFV and 
TFV-DP was 10 ng/ml, 15 ng/ml and 2 ng/ml with R2 values > than 0.99. 
The chromatogram of analytes and internal standards in Figure 3 were obtained using the F5 column. 
The methanol gradient resulted in separation of FTC and ZDV but showed poor resolution for TFV-
DP, EFV and ADV-DP. EIC analysis was performed, allowing for these analytes to be resolved.  
          
Figure 3: A MeOH gradient and B ACN gradient chromatogram of FTC, TFV-DP, EFV and their 
internal standards using a F5 column (n = 6). The respective LOD’s for FTC, EFV and TFV-DP was 





The chromatogram of analytes and internal standards with the ACN gradient (Figure 3B) resulted in 
peak splitting for FTC and broadening of the ZDV peak as well as unresolved peaks for TFV-DP, 
CBB and ADV-DP.  
Figure 4 shows the separation of atripla and its internal standards using the amide column. Separation 
was obtained in FTC, ZDV, TFV-DP, ADV-DP, CBB and EFV however peak broadening was 
observed with respect to TFV-DP under MeOH gradient conditions (Figure 4A). 
          
Figure 4: A MeOH gradient and B ACN gradient chromatogram of FTC, TFV-DP, EFV and their 
internal standards using amide column (n = 6). The respective LOD’s for FTC, EFV and TFV-DP 
was 5 ng/ml, 5 ng/ml and 3 ng/ml with R2 values > than 0.99. 
The chromatogram of analytes and their internal standards are shown in Figure 4B were separated 
on an amide column and ACN as the mobile phase. Good separation was achieved for FTC, ZDV, 
TFV-DP, ADV-DP, CBB and EFV. However, peak splitting was observed for FTC together with 
broadening of ZDV and lower intensity.  
2.4.1 Accuracy and precision 
The intra‐ and inter‐day precision and accuracy in plasma are presented in Tables S1 to S3 
(Supplementary information). FTC showed intra‐ and inter‐day precisions with an RSD percentile 
ranging from 0.25 to 5.22 %, and the EFV analyte in plasma ranging from 0.31 to 6.73 %. TFV-DP 
showed intra‐ and inter‐day precisions of 0.26 to 8.59 % RSD. The accuracy and precision for the 
method was well within acceptable limits according to EMA guidelines which were within 15% for 
the LQC, MQC and HQC and within 20 % for the the LLOQ. 
2.4.2 Extraction recovery 
The plasma recovery of FTC, EFV and TFV-DP in the C18, biphenyl, F5 and amide columns are 




recoveries ranging from 4.46 to 9.59 % RSD. The biphenyl recoveries ranged from 0.12 to 11.45 % 
RSD and the amide column showed RSD percentages ranging from 0.99 to 11.92%. The accuracies 
and precisions determined were within acceptable limits according to EMA guidelines and 
reproducible in all triplicates tested. The actual recoveries ranged from 43.61 to 62.62 % for FTC, 
from 47.54 to 93.92 % for EFV and 52.10 to 58.19 for TFV-DF which is typical for the recovery of 
HIV drugs from plasma.  
Table 1: Extraction recovery of FTC, EFV and TFV-DP in plasma across the different columns used 





















LQC 47.74 (10.21) 52.05 (8.72) 58.19 (4.06) 
MQC 47.24 (2.96) 49.10 (4.32) 57.52 (2.22) 
HQC 41.36 (13.99) 51.46 (2.97) 56.47 (2.76) 
 
F5 
LQC 62.62 (8.43) 93.92 (11.25) 58.00 (3.83) 
MQC 69.61 (4.46) 97.94 (4.69) 57.06 (9.37) 
HQC 62.82 (4.92) 91.40 (9.59) 59.43 (6.90) 
 
Biphenyl 
LQC 62.16 (7.79) 47.54 (5.77) 58.35 (3.03) 
MQC 86.43 (3.64) 61.62 (5.15) 69.68 (0.55) 
HQC 40.37 (11.45) 54.34 (1.81) 69.47 (0.12) 
 
Amide 
LQC 43.61 (10.47) 72.65 (11.92) 52.10 (1.00) 
MQC 45.95 (2.21) 70.94 (0.99) 64.13 (7.06) 
HQC 51.18 (1.23) 86.74 (3.20) 56.73 (5.01) 
 
2.4.3 Resolution 
A resolution of 1.5 or greater represents efficient separation of two peaks [28, 30, 31]. The resolution 
on the C18 column was 1.28 and 0.50 for FTC & ZDV and ADV-DP & CBB, respectively. The 
43 
 
resolutions on the biphenyl column were calculated for FTC & ZDV, TFV & ADV and ADV-DP & 
CBB and were found to be 1.55, 0.94 and 1.83 respectively. The resolution on the F5 column ranged 
between 1.14 and 3.08. The resolutions of FTC & ZDV and ADV-DP & CBB were calculated for the 
amide column and was found to be 1.00 and 1.60, respectively, with the other peaks not being 
resolved. Overall the most acceptable resolution was observed on the F5 and biphenyl columns, using 
MeOH as the mobile phase. 
2.4.4 Asymmetry factor and theoretical plates 
The asymmetry factor (As) was one of the tools that were applied to determine the efficiencies of 
the column gradient methods. A value of 1 indicates symmetric peaks, while a As < 1 indicates 
peak fronting and As > 1 representing peak tailing. The results showed that the biphenyl column 
(Table 2) performed most consistently with only a slight peak tailing, while the other columns 
exhibited both tailing and fronting for different analytes. 
The number of theoretical plates (N) was one of the tools used to measure column efficiencies; it 
shows the peak dispersion on the column which is a reflection of performance [25, 30, 31]. Table 2 
summarizes the N determined for each column. The N for each compound varied from column to 
column, with the amide performing best for FTC and the biphenyl and C18 for TFV-DP and EFV, 
respectively. 
Table 2: Mean asymmetric factors and theoretical plates per metre for FTC, EFV and TFV-DP in all 
evaluated columns  
Asymmetric factor 
 
FTC ZDV TFV-DP ADV-DP CBB EFV 
C18 0.99 1.17 0.78 1.16 1.07 1.03 
Biphenyl 1.18 1.24 1.2 1.19 1.11 1.16 
F5 1.21 1.15 0.84 0.87 1.12 1.16 
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Amide 1.28 1.09 1.05 1.14 1.11 0.61 
Number of theoretical plates 
C18 36.00 95.60 909.3 5329 5625 23511 
Biphenyl 40.96 225.0 5057 6250 6688 6241 
F5 31.36 144.0 3863 3738 45511 10404 
Amide 49.00 121.0 676.0 2460 3136 18860 
 
2.5. Conclusion 
In this study, the efficiencies of new fused-core particle columns with the different active matrix 
groups which were C18, biphenyl, F5, and amide were compared based on their ability to separate 
the current HIV ARV one-a-day pill (Atripla) with its respective internal standards. The data 
obtained from this study clearly indicates that the biphenyl column is most suitable for TDM of 
Atripla in plasma, when using a methanol gradient method. The biphenyl phase also showed to have 
the most acceptable resolution and asymmetric factors when compared to the C18, F5 and, amide. 
However, this does not rule out the use of other columns for different applications than those 
intended in this study, which was the separation of the current first-line HIV therapy. Ultimately the 
choice of column is determined by the analyte one wishes to investigate as well as its properties, 
which each column having its own advantages as discussed.  
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2.8 Supplementary information 
2.8.1 Methods 
Formulae used in calculations of resolution, asymmetry factor and theoretical plates 
The resolution was calculated based on Eq. 1 shown below: 
𝑅 =
2 ( 𝑡𝑅2 −  𝑡𝑅1 )
𝑤𝑏1 + 𝑤𝑏2
                                                                                                                             (1) 
Where Rs is the resolutions between two peaks, tR1 and tR2 is the retention time of the first and second 
peak respectively, wb1 and wb2 is the width at the base of the first and second peak, respectively. The 
resolution was calculated in all four columns. 
Eq. 2 below was used to calculate the number of theoretical plates for each stationary phase: 
𝑁 = 16 (
𝑡𝑅
𝑤𝑏
)2                                                                                                                                        (2) 
Where N is the number of theoretical plates, tR is the retention time, and wb is the width at the base of 
the peak. 
The asymmetry factor (As) is one of the tools that are applied to indicate the efficacy of the column 
gradient methods, where a, is the width of the front half of the peak, and b, is the width of the back 
half of the peak. A value of 1 indicates symmetric peaks, while a As < 1 indicates peak fronting and 









2.8.2.1 Accuracy and precision 
Table S1: Intra and inter‐day precision and accuracy for the analysis of FTC in plasma (n = 6). 
QC 
Levels 
Conc (ng/mL) F5 C18 Biphenyl Amide 
LLOQ 
20 Mean (%) 20.27 22.07 18.03 20.24 
Accuracy (%) 101.33 110.38 90.93 101.18 
Intra-day(% RSD) 1.43 0.35 0.77 4.53 
Accuracy (%) 103.77 111.44 104.98 101.50 
Inter-day (% RSD) 3.06 0.25 0.99 4.22 
LQC 
100 Mean (%) 94.27 110.29 98.36 96.09 
Accuracy (%) 94.27 110.29 97.73 96.09 
Intra-day (% RSD) 1.21 0.84 2.13 3.72 
Accuracy (%) 104.65 112.14 92.21 93.40 
Inter-day (% RSD) 1.73 0.86 1.52 5.22 
MQC 
500 Mean (%) 500.69 475.1 528.05 513.78 
Accuracy (%) 100.14 95.02 105.13 102.76 
Intra-day (% RSD) 3.08 1.00 3.50 4.60 
Accuracy (%) 99.81249 107.22 97.40 96.80 
Inter-day (% RSD) 2.984731 0.52 2.15 5.231245 




Table S2: Intra and inter‐day precision and accuracy for the analysis of EFV in plasma. (n = 3 days, 
three replicates per day) 
QC 
Level 





Mean (%) 18.31 22.18 18.9 17.67 
Accuracy (%) 91.82 110.89 94.51 88.33 
Intra-day (% RSD) 6.38 1.63 1.78 8.28 
Accuracy (%) 90.62 103.25 95.14 105.40 





Mean (%) 110.75 87.26 110.82 95.76 
Accuracy (%) 110.75 87.26 110.82 95.76 
Intra-day (% RSD) 1.63 0.85 3.13 1.89 
Accuracy (%) 105.99 98.16 103.84 103.56 
Inter-day (% RSD) 1.35 0.49 3.33 2.47 
MQC 500 Mean (%) 532.59 562.07 428.41 533.78 
Accuracy (%) 92.58 91.92 93.71 102.93 
Intra-day (% RSD) 2.66 1.43 1.21 3.91 
Accuracy (%) 96.50618 103.96 96.22 102.94 




Accuracy (%) 106.52 112.41 85.68 106.76 
Intra-day (% RSD) 1.83 0.58 0.31 2.82 
Accuracy (%) 103.78 106.04 88.48 110.42 





Mean (%) 1655.64 1434.83 1309.1 1510.61 
Accuracy (%) 110.38 95.66 87.27 100.71 
Intra-day (% RSD) 1.79 1.32 2.29 2.52 
Accuracy (%) 99.44 94.09 86.30 103.90 
Inter-day (% RSD)  
2.54 1.40 1.13 2.96 
 
Table S3: Intra and inter‐day precision and accuracy for the analysis of TFV-DP in plasma. (n = 3 
days, three replicates per day) 
QC 
Level 





Mean (%) 9.82 10.71 10.71 10.65 
Accuracy (%) 98.18 107.13 107.08 106.50 
Intra-day (% RSD) 3.02 1.21 3.36 8.59 
Accuracy (%) 97.35 101.09 107.08 105.99 
Inter-day (% RSD) 3.46 0.78 3.36 2.37 





Accuracy (%) 97.03 89.22 99.24 89.73 
Intra-day (% RSD) 0.93 0.98 7.65 2.00 
Accuracy (%) 92.95 98.37 99.24 89.50 





Mean (%) 270.09 233.82 277.69 219.3 
Accuracy (%) 108.04 93.53 111.08 87.72 
Intra-day (% RSD) 0.95 0.30 2.89 2.48 
Accuracy (%) 96.82 95.00 111.08 93.98 





Mean (%) 853.11 801.96 850.65 664.57 
Accuracy (%) 113.75 106.93 113.42 88.61 
Intra-day (% RSD) 0.26 0.57 4.33 1.01 
Accuracy (%) 105.30 97.00 113.42 90.68 
  Inter-day (% RSD) 1.78 0.88 4.33 2.80 
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Tuberculosis (TB) remains the most common opportunistic disease in HIV positive patients. TB 
worsens the symptoms of an HIV infection in co-infected patients and vice versa. HIV-positive 
patients, who are co-infected with TB, firstly use antiretroviral therapy (ART) for a few months before 
being introduced to TB treatment. AtriplaTM is the first-line combination drug for HIV treatment, 
which consists of efavirenz (EFV), emtricitabine (FTC) and tenofovir disoproxil fumarate (TFV-DP).  
The emergence of multi-drug resistant TB (MDR-TB) has presented the need for second-line TB 
drugs for the effective treatment of resistant bacteria. Streptomycin (STR), kanamycin (KAN) and 
ofloxacin (OFL) are some of the second-line drugs commonly used to treat MDR-TB, in HIV 
complicated patients. Studies regarding therapeutic drug monitoring (TDM) of antiretrovirals 
(ARV’s) and TB drugs are extremely important in order to understand the effective dose and duration 
of treatment, in order to maximize patients’ benefits while minimizing the risk of adverse drug effects. 
Therefore, the aim of this study is to develop, optimize and validate a liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) method for the simultaneous quantification of first-line anti-HIV 
drugs (EFV, FTC and TFV) and second-line anti-TB drugs (KAN, OFL and STR) in rat plasma for 
the usage of TDM. Chromatographic separation of analytes was performed on a biphenyl column 
(5cm x 2.1 mm, 2.7 mm; pore size of 90 Å), mobile phase A was (H2O + 0.1% FA) and mobile phase 
B was (MeOH + 0.1% FA). Mass spectrometric detection was performed in positive electrospray 
ionization mode using multiple reaction monitoring. Evaluation of assay performance included 
accuracy and precision, linearity, stability, matrix effect and recoveries in plasma. The LC-MS/MS 
method reported here meets all the European Medicine’s Agency (EMA) guidelines for use in clinical 
trials and for the simultaneous determination of the effective plasma concentrations of anti-TB and 
anti-HIV drugs, in addition its short analysis times make it a strong candidate for TDM in a point of 
care setting. 






Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) has been 
recognized as a global health threat for the past three decades, in the 1980’s there were only a few 
deaths due to this disease, however this is no longer the case as mortality has rapidly increased over 
the past ten years [1-4].  In 2016, there were approximately 36 700 000 and 7 100 000 HIV positive 
patients globally [5].  Highly active antiretroviral therapy (HAART) has become an essential 
treatment strategy for patients suffering from HIV infection [6].  However, this treatment has been 
proven to come with serious adverse effects [7]. This has posed challenges with regards to the 
acceptable HAART plasma concentration required to avoid toxic effects while maintaining 
therapeutic efficacy [8]. 
Patients with an HIV infection are most likely to contract tuberculosis (TB), more than any other 
opportunistic disease [5, 9]. Simultaneous treatment of TB and HIV is required for HIV-positive TB 
patients in light of the fact that TB has been recognized as the major cause of death in developing 
countries, especially among individuals with a compromised immune system [9, 10]. In 2015, 55% 
of TB patients globally were tested for HIV and amongst them, 15% were HIV positive [5]. TB 
contributed  35% of global mortality in individuals with HIV/AIDS in 2015 [5]. In 2015, 
approximately 480 000 people, globally developed multidrug-resistant TB (MDR-TB) [5]. The 
development of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (M.tb) has been 
disturbing medical experts around the world [11, 12]. These statistics prove that MDR-TB continues 
to be one of the major problems facing health professionals [5]. A combination of second-line TB 
drugs, which are expensive, are required for the successful treatment of MDR-TB [9]. 
There are currently five classes of ARV’s available namely; nucleoside and nucleotide reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), Integrase inhibitors (InSTIs) and fusion inhibitors. Each of these classes inhibits a 
specific stage in the HIV replication cycle [13, 14]. The current first-line HIV treatment consists of a 
triple ARV combination generally comprises of two NRTIs and an NNRTI or PI in order to target 
various stages of the viral cycle, this combination is a one-day-pill, known as AtriplaTM. 
AtriplaTM was approved in July 2006 by the US Food and Drug Administration (FDA). This 
combination presents the most effective dosing strategy and the minimal number of pills for treatment 
of HIV [15, 16], this combination includes two NRTIs [emtricitabine (FTC) and tenofovir disoproxil 
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fumarate (TFV-DP)], and one NNRTI [efavirenz (EFV)] [8]. The NRTIs mimic the normal 
nucleotides of DNA, inhibiting transcription of viral RNA to DNA while the NNRTIs change the 
conformation of the catalytic site of reverse transcriptase and completely prevents its action [13]. The 
major disadvantage for AtriplaTM is that it combines each of its individual components’ adverse 
effects. Some common effects include abdominal pain, rash, anxiety, back pain, paresthesia, skin 
discoloration particularly on the soles of the feet and palms caused by FTC. EFV is known to cause 
headaches, insomnia, dizziness, inability to concentrate, and nightmares while TFV is known to cause 
vomiting, diarrhoea, renal failure, nausea, asthenia, proteinuria, and flatulence [7, 17-19]. 
Streptomycin (STR), kanamycin (KAN) and ofloxacin (OFL) are second-line drugs that fall within 
the aminoglycoside and fluoroquinolone groups, respectively, and are commonly prescribed for the 
treatment of MDR-TB [9, 20-22]. Second-line TB drugs are costly and have more serious side effects 
than first-line TB drugs [9]. Some common side effects include anorexia, nausea, diarrhoea, skin or 
hypersensitivity reactions, vomiting, and central nervous system events caused by OFL. STR is 
known to cause a rash, vertigo, deafness, headache, sterile abscesses at injection spots, and 
hypersensitivity while KAN causes azotaemia, stomach pains, hearing loss, ataxia, anxiety, 
nystagmus, serum electrolyte abnormalities, thrush, and tremulousness headache [21, 23-25]. 
In a recent review, Coyne et al. (2009) stated that drug interactions among aminoglycosides and 
NRTIs or NNRTIs are possible. However, the use of standard doses and to monitor renal function is 
recommended since TFV has the risk of additive renal toxicity [25]. It further stated that interactions 
among fluoroquinolones and NNRTIs or NRTIs are rare but also possible. However, oral absorption 
of fluoroquinolones is reduced by buffered drugs, therefore, they should be taken 6 hours after or 2 
hours before the use of any buffered drugs and caution should be taken when these drugs are used 
with drugs associated with renal dysfunction, such as TFV [25].  
Investigations regarding therapeutic drug monitoring (TDM) of antiretroviral (ARV) drugs are highly 
important in order to understand the effective dose, frequency of dosing and duration of treatment.  
This could reduce toxicity levels and the cost of the therapy [8, 26, 27].  Further clinical trials are 
required before TDM can be accepted as a standard tool in the management of HIV therapy [28].  
The treatment of HIV patients co-infected with TB can be very complicated, especially due to drug-
related factors such as toxicity, adherence to therapy, drug resistance, and complex drug interactions. 
Therefore, it is vital to study the TDM of HIV patients co-infected with TB since TDM will be helpful 
in determining the effective plasma concentration levels of anti-TB and anti-HIV drugs that present 
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minimum drug interactions and adverse effects [29, 30]. To our knowledge, no studies exist regarding 
the development of an LC-MS method for the simultaneous detection of HIV and TB drugs.  
Therefore, the aim of this study is to develop, optimize and validate a liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) method for the simultaneous quantification of anti-HIV drugs (FTC, 
EFV, and TFV) and second-line anti-TB drugs (STR, KAN, and OFL) in rat plasma for the usage of 
TDM. 
3.3 Materials and methods 
3.3.1 Reagents and standards  
EFV was purchased from Adcock Ingram (South Africa).  TFV, KAN, STR and OFL were purchased 
from Sigma Aldrich (South Africa).  FTC was purchased from Mylan (South Africa). Internal 
Standards, 4-(4-Carboxybenzyl)-2H-1, 4-benzoxazin-3(4H)-one (CBB), adefovir dipivoxil (ADV-
DP), amikacin (AKN), dihydrostreptomycin (DHSTR) and ciprofloxacin (CFL) were all purchased 
from Sigma Aldrich (South Africa) except for lamivudine (3TC) which was purchased from Aspen 
pharmacare (South Africa). LC-MS grade solvents; acetonitrile (ACN) and methanol (MeOH) were 
purchased from Sigma Aldrich (South Africa). Analytical grade formic acid (FA) was purchased from 
Merck Millipore (Merck, South Africa). Water was purified with a Milli-Q purification system from 
Millipore Corporation (Bedford, MA, USA). HLB-SPE cartridges (30 mg, 1.0 mL) were purchased 
from Supelco-Sigma (St. Louis, MO).  
3.3.2 Calibration standards and quality control samples 
Separate stock solutions of target analytes and internal standards were prepared by dissolving 1 mg 
of each HIV drug in 1 mL of MeOH and dissolving 1 mg of each TB drug in 2 mL of MeOH and 
water (50:50 v/v). All prepared stock solutions were stored at –20 ◦C. The appropriate serial dilutions 
of the stock solutions were done to prepare the working standard solutions of target compounds and 
internal standards in MeOH and water (50:50 v/v). Calibration standards that were prepared ranged 
from 10 to 1000 ng/mL for TFV and OFL, 20 to 2000 ng/mL for EFV, FTC, STR and KAN.  The 
quality control (QC) samples were prepared at lower limit of quantification (LLOQ), low quality 
control (LQC), middle quality control (MQC) and high-quality control (HQC) to give the final 
concentration levels of 10, 20, 250 and 750 ng/mL for TFV, and OFL, 20, 60, 500 and 1500 ng/mL 
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for EFV, FTC, STR and KAN. Internal standard concentrations were 250 ng/mL for ADV-DP and 
AKN, 500 ng/mL for CBB, 3TC, DHSTR and CFL.  
3.3.3 Instrumentation and chromatographic conditions  
Analysis and validation were performed using an LC-MS/MS system comprised of an Agilent 1100 
series high-performance liquid chromatography (HPLC) system coupled to MicroTOF-Q II 
electrospray ionization (ESI) time-of-flight mass spectrometry (TOF-MS) instrument (Bruker 
Daltonics, Bremen, Germany). Chromatographic separation was performed using an Ascentis 
Express biphenyl analytical column with dimensions of 5 cm × 2.1 mm, a particle size of 2.7μm and 
pore size of 90 Å. The analytes and internal standards were eluted using a gradient mobile phase 
system comprising of mobile phase A (H2O + 0.1% v/v FA) and mobile phase B (MeOH + 0.1% v/v 
FA) and the flow rate was set at 0.35 mL/min. The gradient method started from 53% mobile phase 
B, increased to 95% over 3 min then held for 5 min before being returned to the initial composition 
over 3 min. The column equilibration time was 3 min.  
The MS parameters were optimized based on the mass-to-charge ratio (m/z) for the detection of EFV, 
FTC, TFV, STR, OFL and KAN including their internal standards; CBB, 3TC, ADV-DP-DP, 
DHSTR, CFL and AKN, respectively. Source parameters were: source type, ESI; ion polarity, 
positive; end plate source, -500 V; nebulizer, 1.8 bar; dry gas, 8.0 L/min; capillary, -4500V; dry 
temperature, 200 ◦C; mass range, m/z 50 → 700; collision cell radiofrequency, 200 Vpp; collision 
energy, 10 eV. Multiple-reaction monitoring (MRM) was performed to yield the mass transitions of 
analytes and internal standards shown in Table S1. All the data was analyzed using Data Analysis 
4.0 SP 5 and Quant Analysis 2.1 (Bruker Daltonics).  
3.3.4 Method validation 
Method validation was conducted according to the European Medicines Agency (EMA) guidelines 
for bioanalytical method development [31].  
3.3.4.1 Specificity and selectivity 
The specificity and selectivity of the method were evaluated by analyzing six blank rat plasma 
samples at LLOQ level. All blank samples were analyzed in the MRM mode following the sample 
preparation procedure and LC-MS/MS conditions. The results were compared to chromatograms 
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obtained for a pure standard solution at the LLOQ level to investigate the potential interferences on 
the target compounds and internal standards.  
3.3.4.2 Linearity and lower limit of quantification 
A signal-to-noise ratio (S/N) of 3:1 was used for determining the limit of detection (LOD) and the 
LLOQ was determined by an S/N ratio that was 5X to that of the LOD. The calibration curves were 
constructed by plotting the peak area ratio of analyte to internal standard against the theoretical 
concentrations of the analyte. The criteria for calibration range included a correlation coefficient (R2) 
≥ 0.99 [32]. The calculated concentrations of the calibration standards should be within ±15% except 
for the LLOQ which should be within ±20% deviation as per EMA guidelines [31]. 
3.3.4.3 Accuracy and precision 
Accuracy was determined as the percentage between the measured concentration of the target 
compounds and their nominal concentration levels. Intra-day and inter-day accuracy and precision 
were assessed by assay of six replicates of different QC levels (LLOQ, LQC, MQC, and HQC) the 
same day and on three different days. The accuracy must be within ± 15% of the nominal 
concentration and for precision, the percentage relative standard deviation (%RSD) must be within 
±15% [31]. 
3.3.4.4 Matrix effect and extraction recovery 
Matrix effect and extraction recovery of the analytes were estimated at the three QC levels (LQC, 
MQC and HQC) in six replicates. Extraction recovery in brief, 50 µL of rat plasma, 10 µL of 1.9 M 
ammonium acetate and 10 µL of 3 M hydrochloric acid was spiked with the appropriate amount of 
each analyte, in order to attain the desired QC concentrations. Thereafter, the sample was made up to 
1 mL using LC-MS grade MeOH and vortexed for 1 minute. The mixture was then centrifuged at 15 
000 rpm, 4 C for 15 minutes. The supernatant was subjected to SPE using the Supel- SELECT HLB: 
30mg/1 mL SPE cartridge (Supelco, Sigma Aldrich, Germany), which gave the most reproducible 
recoveries. The SPE cartridge was conditioned with 1 mL of MeOH. The supernatant was then passed 
through the SPE cartridge. The eluent was collected in an HPLC vial and vortexed, prior to injection 
into the LC-MS system. The matrix effect was evaluated on six lots of blank plasma from different 
sources, as requested by guidelines. Peak areas from blank extracts spiked with all analytes at three 
QC levels (post-extraction addition samples) were compared with peak areas from standard solutions 
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spiked with analytes at the same concentration level. The matrix effect was calculated as percentage 
of deviation of the peak areas obtained from the plasma extracts with the ones obtained from the 
standard solutions. Matrix factor should be within ± 15% [31].  
3.3.4.5 Stability 
Batch samples stay longer in the autosampler due to queued injections. Therefore, the autosampler 
stability of analytes was evaluated analyzing prepared samples stored in the auto-sampler for a period 
of 24 h before injection. The freeze-thaw stability was assessed after exposing QC samples to three 
freeze-thaw cycles. The 6-hour short term stability of the analytes on the bench top was also 
investigated. All stability experiments were evaluated at the four QC levels (LLOQ, LQC, MQC and 
HQC).  
3.4 Results and Discussion 
3.4.1 LC-MS/MS method optimization 
The results of the mass transitions of the samples optimized and retention times obtained are shown 
in Table S1. The chromatogram is shown in Figure 1. Currently, there are no available studies that 
have developed and validated an LC-MS method for the simultaneous quantification of first-line anti-
HIV drugs and second-line anti-TB drugs. To our knowledge, this current study is the first of this 
kind. However, numerous studies have been conducted for the LC-MS quantification of HIV and 
second-line TB drugs, separately. These results are similar to the ones that are already available with 





Figure 1: Chromatogram showing the simultaneous detection of three HIV and TB drugs with their 
internal standards 
Key 
FTC - Emtricitabine 3TC - Lamivudine 
TFV - Tenofovir ADV-DP - Adefovir dipivoxil 
EFV - Efavirenz CBB - 4-(4-Carboxybenzyl)-2H-1, 4-benzoxazin-3(4H)-
one 
STR - Streptomycin DHSTR - Dihydrostreptomycin 
OFL - Ofloxacin CFL - Ciprofloxacin 
KAN - Kanamycin AKN - Amikacin 
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3.4.2 Method validation 
An LC-MS/MS method for simultaneous quantification of first-line HIV drugs and second-line TB 
drugs in rat plasma was developed and validated with respect to specificity and selectivity, linearity 
and lower limit of quantification, accuracy and precision, stability, matrix effects and recovery. All 
criteria for bioanalytical method validation based on the EMA guidelines were satisfied [31]. 
3.4.2.1 Specificity and selectivity 
The specificity and selectivity were evaluated by comparing the chromatograms of the drug-free rat 
plasma with the corresponding spiked plasma samples. No significant interfering peaks were 
observed due to endogenous compounds. Co-eluting compounds were differentiated from each other 
by the MRM’s ability to deliver a unique fragment ion for each compound that is monitored and 
quantified (mass transition) in a matrix. A fragmented mass is also distinguished by extracted ion 
chromatogram (EIC). Results were within the acceptance criteria where the response was < 20% of 
the LLOQ for all the analytes and 5% for all the internal standards. 
3.4.2.2 Linearity and lower limit of quantification 
The LODs concentrations ranged from 1 to 10 ng/mL. All calibration curves had the correlation 
coefficients (R2) of greater than 0.99, shown in Table 1. The calibration standards were also within 
the acceptance criteria recommended by the EMA guidelines [31]. The calibration standards ranged 
from 10 to 1000 ng/mL for OFL and TNV, 20 to 2000 ng/mL for EFV, FTC, KAN, and STR. The 
concentrations for internal standards were 250 ng/mL for ADV-DP and AKN, while it was 500 ng/mL 
for 3TC, CBB, CFL, and DHSTR. 

















3.4.2.3 Accuracy and precision in plasma 
The results for accuracy and precision of the proposed method are shown in Table S2. Intra-day 
accuracy varied from 88.68% to 107.47% and inter-day accuracy from 90.99% to 104.99%. The intra-
day precision varied from the %RSD of 0.64% to 9.71% and inter-day from 1.56% to 12.77%. These 
values are within the acceptance criteria of ±15% recommended by the EMA guidelines [31]. 
3.4.2.4 Stability  
The results for the stability of the analytes are shown in Table 2. The stability in all evaluated 
conditions varied from 87.25% to 107.85% with the %RSD varying from 0.22% to 11.36%. These 
values are within the acceptance criteria of ±15% recommended by the EMA guidelines [31]. This 
confirms that all analytes were stable in all evaluated conditions. 
Table 2: Stability of EFV, KAN, FTC, STR, OFL and TFV in plasma (n = 6) 
 
  
 QC levels 
   LLOQ LQC MQC HQC 
Storage condition Analyte 
Concentration 
(ng/mL) 
20 60 500 1500 
Bench-top, 6 h, RT  EFV Mean  18.68 58.67 529.00 1562.40 
  
Accuracy (%) 93.38 97.78 105.80 104.16 
  

















Accuracy (%) 103.36 95.11 101.40 96.16 
  















Accuracy (%) 103.55 101.08 99.55 89.13 
  
(% RSD) 6.66 6.91 6.16 1.43 
 
      
      
64 
 
STR Mean  18.27 60.64 509.80 1611.00 
  
Accuracy (%) 91.34 101.06 101.96 107.40 
  (% RSD) 3.25 0.22 2.52 1.00 
Three freeze-thaw 





















Accuracy (%) 103.71 102.75 106.97 93.79 
  















Accuracy (%) 90.88 103.87 100.48 103.71 















Accuracy (%) 95.07 87.25 101.99 90.36 
 















Accuracy (%) 103.53 104.94 94.44 107.18 
  (% RSD) 1.65 1.34 3.93 0.83 















Accuracy (%) 92.38 95.26 96.87 104.19 
  
















Accuracy (%) 105.89 93.38 102.30 97.55 
  















Accuracy (%) 101.72 97.47 103.55 91.14 
  

















Accuracy (%) 90.99 99.16 100.78 107.63 
  (% RSD) 3.08 0.73 2.59 1.08 
Stability Analyte 
Concentration 
(ng/mL) 10 20 250 750 














Accuracy (%) 97.21 98.28 104.42 97.32 
  
(% RSD) 1.24 4.26 5.16 6.28 
 
 
OFL Mean  9.22 19.45 239.4 744.98 
  
Accuracy (%) 92.17 97.25 95.76 99.33 
  




TFV Mean  9.66 21.57 241.63 762.68 
  
Accuracy (%) 96.63 107.85 96.65 101.69 
  
(% RSD) 5.23 1.13 1.38 1.25 
 
 
OFL Mean  10.62 18.51 259.98 780.08 
  
Accuracy (%) 106.23 92.56 103.99 104.01 
  
(% RSD) 1.30 1.37 1.21 3.33 
Autosampler, 24 h, 
RT 
 
TFV Mean  9.72 19.36 266.4 709.95 
  
Accuracy (%) 97.16 96.82 106.56 94.66 
  
















Accuracy (%) 91.45 98.04 94.79 98.17 
 
 
(% RSD) 1.66 1.06 1.68 1.17 
RT: Room temperature 
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3.4.2.5 Matrix effect and extraction recovery 
The results for matrix effect and extraction recovery are shown in Table 3. The recovery of all six 
analytes ranged from 85.3% to 107.4% with the %RSD ranging from 0.21% to 7.66%. These 
recoveries indicate that the method was reproducible for each compound. The matrix factor of all six 
analytes ranged from -12.98% to 5.87% with the %RSD ranging from 0.28% to 12.62%, which was 




Table 3: Matrix effect and extraction recovery of EFV, KAN, FTC, STR, OFL and TFV in plasma (n=6) 
Analyte QC Level 
Concentration 
(ng/mL)  




EFV Low 60 96.9 2.75 -6.71 3.65 
 Middle 500 100.9 0.89 0.12 0.28 
 High 1500 100.3 0.07 1.07 0.77 
FTC Low 60 95.7 2.16 -6.83 2.52 
 Middle 500 90.1 7.46 -10.46 7.50 
 High 1500 95.3 1.00 -3.36 4.41 
TFV Low 20 86.3 0.21 -9.15 4.20 
 Middle 250 104.2 2.22 0.65  3.06 
 High 750 85.3 2.46 -12.98 4.03 
KAN Low 60 98.9 1.59 -1.92 2.38 
 Middle 500 97.6 0.81 -2.49 0.33 
 High 1500 106.2 2.02 5.87 11.71 
STR Low 60 89.8 3.32 -7.21 4.32 
 Middle 500 105.7 5.51 1.60 12.62 
 High 1500 99.1 2.66 -8.25 0.77 
OFL Low 20 91.3 4.85 -11.35 0.40 
 Middle 250 95.2 7.66 -7.76 10.70 
 High 750 107.4 2.12 5.85 3.86 
68 
 
TDM has been utilized in the management of treatment of different health background conditions 
to guarantee ideal therapeutic advantages while limiting adverse effects [33, 34]. For a very long 
time, TDM for anti-HIV drugs and anti-TB drugs has been identified as a critical tool required 
for the optimization of HIV and TB treatment programs [33, 34]. A validated LC-MS/MS method 
is the primary requirement for successfully determining the plasma drug concentrations and 
pharmacokinetic parameters in TDM [33-35]. Validated LC-MS/MS methods for quantification 
of anti-HIV and anti-TB drugs, individually, are available [8, 33, 36-39].  
The linearity, accuracy and precision of assay must be determined, and evaluated to verify that 
the analytical range of the method is adequate to cover the accepted plasma drug concentrations. 
The R2, for all analytes was greater than 0.99 with the accuracy and precision ranging from 
88.68% to 107.47%, all of which were well within the specifications of the EMA. Specificity and 
sensitivity studies was performed to determine the extent of interference from the drug 
combination and drug metabolites, this analytical method showed no significant interference with 
respect to the separation of the analytes. Optimization of sample preparation was done to limit 
matrix effects in the assay using solid phase extraction [34]. Matrix effect occurs when 
components in the sample matrix co-elute with the analytes of interest, which changes the signal, 
leading to low detection of the analytes, quantitation inaccuracy and low method robustness. The 
plasma recovery ranged from 85.3% to 107.4% which is within the ±15% recommended by EMA 
guidelines, thus suitable for TDM studies with the matrix effects ranging from -12.98% to 5.87%. 
All the parameters monitored in this study were well within the acceptable range as recommended 
by the EMA. 
All these parameters are essential in method validation were performed to validate the optimized 
method presented in this study. In this study, we present the LC-MS/MS method with the total 
run time short to 11 minutes which is convenient for TDM of a large number of HIV positive TB 
patients. In addition to TDM, this method has applications for clinical trials and pharmacokinetic 
studies of HIV positive and MDR-TB patients.  
3.5 Conclusion 
The LC-MS/MS method developed, optimized and validated in this study allows for the precise, 
rapid and reproducible simultaneous quantification of first-line antiretroviral drugs (EFV, FTC, 
and TFV) and second-line TB drugs (KAN, STR and OFL) in plasma. This is the first such LC-
MS/MS method to be developed and validated for simultaneous quantification of first-line HIV 
drugs and second-line TB drugs aimed at TDM. TDM is useful in improving the combined 
efficacy of TB and HIV treatment. This ensures that each patient is given suitable drug doses in 
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order to maintain plasma drug concentration within the therapeutic window, minimizing the 
incidence of drug-drug interactions and adverse effects. 
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Figure S2: Chemical structures of second-line anti-tuberculosis drugs 
 
3.8.2 Methods 
The matrix effect was calculated based on equation shown below: 
𝑀𝐸 (%) =  (
𝐴𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑜𝑠𝑡 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑
𝐴𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
− 1) × 100 









Table S1: MRM mass transitions and retention times of analytes with their internal standards  
IS: Internal standard 
Table S2: Accuracy and Precision of EFV, KAN, FTC, STR, OFL and TFV in plasma (n = 6) 
 
 
 QC level 
  LLOQ LQC MQC HQC 
Analyte Concentration (ng/mL) 20 60 500 1500 
EFV Mean  18.58 58.72 526.05 1515.90 
 
Accuracy (%) 92.88 97.87 105.21 101.06 
 













Accuracy (%) 104.13 104.99 101.97 104.82 














Accuracy (%) 89.50 103.94 98.07 97.52 
 
Intra-day (% RSD) 8.08 2.57 1.35 1.25 
 
     
Analyte  
Precursor ion 
[M+H]+ Product ion [M+H]+ 
Retention time (min) 
EFV 316 168 6.1 
FTC 248 130 0.8 
TFV 288 176 0.9 
KAN 485 133 7.2 
OFL 362 261 0.7 
STR 582 311 8.0 
CBB (IS) 284 135 5.6 
3TC (IS) 230 112 0.8 
ADV-DP (IS) 502 256 5.0 
AKN (IS) 586 582 8.0 
CFL (IS) 332 231 0.8 
DHSTR (IS) 584 298 8.0 
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Mean  19.29 57.10 503.85 1523.85 
 
Accuracy (%) 96.47 95.16 100.77 101.59 














Accuracy (%) 107.47 98.78 92.81 88.68 
 













Accuracy (%) 99.99 101.15 94.46 94.31 














Accuracy (%) 106.96 97.77 104.99 106.46 
 













Accuracy (%) 103.16 103.91 100.84 106.13 
 Inter-day (% RSD)  3.36 5.31 9.17 4.33 
Analyte Concentration (ng/mL) 10 20 250 750 
OFL Mean 9.47 18.15 229.83 765.23 
 
Accuracy (%) 94.74 90.77 91.93 102.03 
 
Intra-day (% RSD) 9.71 0.90 0.99 1.39 
 
 
Mean 9.90 19.27 242.73 713.63 
 
Accuracy (%) 98.96 96.36 97.09 95.15 
 
Inter-day (% RSD) 3.98 12.64 12.77 7.03 
 
TFV Mean 10.08 18.2 238.23 688.35 
 
Accuracy (%) 100.83 90.99 95.29 91.78 
 
Intra-day (% RSD) 1.42 1.01 1.00 0.97 
 
 
Mean 10.27 19.34 237.48 727.58 
 
Accuracy (%) 102.73 96.71 94.99 97.01 
 





4.1 Summary of the study  
In chapter 1, it was demonstrated that HIV and TB continue to be major health threats in the 
world, especially as a co-infection. In 2016, WHO estimated the number of HIV positive 
individuals to be approximately 36 700 000, globally. WHO also estimated the global prevalence 
of multi-drug resistant tuberculosis (MDR-TB) to be 490 000 in 2016. In 2016, WHO 
approximated that HIV positive individuals have a 26-fold-higher chance of TB disease 
progression from latent TB infection (LTBI) to active TB when compared with HIV negative 
individuals. TB accounted for 22% of worldwide mortality in people with HIV/AIDS in 2016. 
HIV positive TB patients receive both HIV and TB treatments. Drug-drug interactions are likely 
to occur for the patients receiving at least three drugs for combined treatment. TDM is the ideal 
tool to quantify these interactions and to determine the correct dosage that a specific patient 
requires. TDM is the measurement of specific drug concentrations at time intervals in the patients’ 
plasma. The need to develop an LC-MS/MS method for the simultaneous quantification of anti-
HIV and anti-TB drugs using the best performing HPLC column was identified. This method will 
potentially assist HIV positive TB patients from suffering the serious adverse effects and reduce 
the time spent by these patients in hospitals. 
The main aim of this study was to evaluate the performance of the new column technologies and 
use the one with optimum efficiency to develop and validate an LC-MS/MS method for the 
simultaneous quantification of anti-HIV drugs [emtricitabine (FTC), efavirenz (EFV), and 
tenofovir (TFV)] and second-line anti-TB drugs [streptomycin (STR), kanamycin (KAN), and 
ofloxacin (OFL) in rat plasma for the usage of therapeutic drug monitoring (TDM). FTC, EFV, 
and TFV are the constituents of a one-day pill, AtriplaTM, which presents the most effective dosing 
plan. STR, KAN, and OFL are used for the treatment of MDR-TB, which is defined as the 
resistance at least to rifampicin (RMP) and isoniazid (INH) first-line anti-TB drugs. 
Numerous studies have been conducted for the LC-MS quantification of HIV and second-line TB 
drugs, separately. These studies are useful in the understanding of HIV and MDR-TB treatment, 
individually. These studies focus on a wide range of HIV and second-line drugs, they are not only 
focusing on one group but cover all groups that are available. However, the increasing number of 
HIV and TB co-infected patients makes it hard for clinicians to choose the treatment that will not 
cause drug interactions and side effects for these patients. Therefore, this left a room for 
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researchers to perform studies that combine these two major diseases in order to provide the best 
treatment plan for HIV and TB co-infected patients. 
In chapter 2, evaluation of four new HPLC column technologies was done based on the resolution, 
theoretical plates, asymmetry factor, limit of detection, linearity, accuracy and precision. This was 
accomplished by developing and validating an LC-MS/MS method of simultaneous quantification 
of current first-line anti-HIV treatment (FTC, EFV and TFV) according to EMA guidelines. 
Mobile phases of MeOH and ACN with water were evaluated using a gradient method on all 
columns. The analytes’ limit of detection (LOD) ranged from 1 ng/ml to 15 ng/ml. Linearity was 
determined by the correlation coefficient (R2) which was greater than 0.99 for all the analytes in 
all the columns. FTC, EFV and TFV-DP showed intra‐ and inter‐day precisions with an RSD 
percentage of 0.25 to 5.22 %, 0.31 to 6.73 % and TFV-DP 0.26 to 8.59 %, respectively. The 
recoveries % RSD on the C18, F5, biphenyl and amide column ranged from 2.22 to 13.99 %, 4.46 
to 9.59 %, 0.12 to 11.45 % and 0.99 to 11.92%, respectively. The biphenyl column showed good 
resolution for FTC & ZDV and ADV-DP & CBB and was found to be 1.55 and 1.83, respectively. 
The biphenyl column also showed good peak asymmetry factor, which ranged from 1.11 and 1.24. 
Biphenyl column showed consistency again with regards to the number of theoretical plates when 
compared to the C18, F5 and, RP-amide. However, it was concluded that other columns (C18, F5 
and, RP-amide) may still be used for applications other than those intended in this study, for 
example, the separation of the current drugs (FTC, EFV and TFV) used for first-line HIV therapy. 
The other columns (C18, F5 and RP-amide) that were used in this study have their own advantages 
depending on the objective intended to be accomplished. In addition, these new HPLC column 
matrices offer various benefits such as the potential of saving solvents and short runtimes, 
essential in TDM studies.  
Looking at the short run time and number of compounds in this study, the separation is adequate 
compared to similar studies that have longer run times with only a few compounds being studied.  
In chapter 3, an LC-MS/MS method for the simultaneous quantification of first-line anti-HIV 
drugs (EFV, FTC and TFV) and second-line anti-TB drugs (KAN, OFL and STR) was developed 
and validated according to EMA guidelines using a biphenyl column, which showed optimum 
performance and consistency in chapter 2. Currently, there are no available studies that have 
developed and validated an LC-MS method for the simultaneous quantification of first-line anti-
HIV drugs and second-line anti-TB drugs. To our knowledge, this current study is the first of this 
kind. Mass spectrometric detection was performed in positive electrospray ionization mode using 
multiple reaction monitoring. Evaluation of assay performance included accuracy and precision, 
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linearity, stability, matrix effect and recoveries in plasma. Intra-day accuracy ranged from 88.68% 
to 107.47% with the %RSD of 0.64% to 9.71% and inter-day accuracy from 90.99% to 104.99% 
with the %RSD of 1.56% to 12.77% for all the analytes. Linearity was determined by the R2 which 
was greater than 0.99 for all the analytes. Stability conditions that were evaluated include the 6 h 
bench-top, 24 h autosampler and three freeze-thaw cycles, which together ranged from 87.25% 
to 107.85% with the %RSD of 0.22% to 11.36%. Concluding from these results, all the analytes 
are stable. Matrix effect ranged from -12.98% to 5.87% with the %RSD ranging from 0.28% to 
12.62%. The recoveries ranged from 85.3% to 107.4% with the %RSD of 0.21% to 7.66%. 
Those anti-TB drugs that were structurally similar and belonged to one group had poor separation. 
However, these results are similar to those of other studies that performed an LC-MS/MS method 
for the simultaneous quantification of second-line anti-TB drugs.  
The LC-MS/MS methods reported in this thesis meets all the EMA Guidelines for use in clinical 
trials and for the simultaneous determination of the effective plasma concentrations of anti-TB 
and anti-HIV drugs, making it a strong candidate for TDM in a point of care setting. Effective 
TDM studies will ensure that patients spend less time in hospital thus saving money and time. 
This study covered nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) antiretroviral therapy classes as well as fluoroquinolone 
and aminoglycoside TB drug groups. Therefore, future studies should cover more drugs from 
various antiretroviral therapy classes and more anti-TB drugs from different groups that are 
available. Future research should also perform pharmacokinetic studies of combined HIV and TB 
drugs in animal models before taking it further to clinical trials.  
4.2 Recommendations 
The LC‐MS/MS methods developed and validated herein can readily be used for future studies 
intending to perform simultaneous quantification of first‐line HIV and/or second-line TB drugs 
in rat plasma and is well suited for therapeutic drug monitoring. Thereafter, these methods can be 
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